Cybin Inc. (OTCMKTS:CYBN – Get Free Report)’s share price traded up 1.5% during mid-day trading on Friday . The company traded as high as $9.80 and last traded at $9.78. 158,951 shares traded hands during mid-day trading, an increase of 11% from the average session volume of 143,015 shares. The stock had previously closed at $9.64.
Cybin Price Performance
The firm has a market cap of $4.02 billion, a P/E ratio of -48.90 and a beta of 0.41. The firm’s 50-day moving average price is $3.33 and its 200 day moving average price is $1.37.
Cybin (OTCMKTS:CYBN – Get Free Report) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($0.01) earnings per share (EPS) for the quarter. Analysts forecast that Cybin Inc. will post -0.19 earnings per share for the current year.
Cybin Company Profile
Cybin Inc, a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in Phase 1/2a clinical trial to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine, which is in Phase 1 clinical trial for treating generalized anxiety disorders; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation.
Read More
- Five stocks we like better than Cybin
- What Investors Must Know About Over-the-Counter (OTC) Stocks
- 3 Micro-Caps Set for Major Moves: Balancing Risk and Opportunity
- Using the MarketBeat Dividend Tax Calculator
- Autodesk Named a “Top Pick” by Morgan Stanley—Is It Time to Buy?
- About the Markup Calculator
- 4 Quirky ETFs With Big Potential for Impressive Gains
Receive News & Ratings for Cybin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cybin and related companies with MarketBeat.com's FREE daily email newsletter.
